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MicroRNAs (miRNAs) are a class of single-stranded small non-coding RNAs. Study of 
miRNAs has been a fast growing field since the first miRNA was discovered in 1993. Many 
findings indicate that miRNA plays an important role in regulating crucial processes in gene 
development. In this research, we designed and implemented a framework called miRCancer, 
which is the first comprehensive database for miRNA expression profiles in human cancers 
based on experimental results. miRCancer also includes an integrated microRNA sequence 
analysis toolkit to help researchers discover possible relationships and functionalities of miRNAs. 
Text mining was used to automatically extract miRNA expression information from online 
electronic literatures. A new coding system, EICD-O, was introduced to annotate miRNA 
expressions in cancers.
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Chapter 1 INTRODUCTION 
MicroRNAs (miRNAs) are a class of single-stranded small non-coding RNAs, many findings 
suggested that miRNA plays an important role in regulating crucial processes in gene development. In 
this research project, we designed and constructed the first comprehensive database for 
microRNA (miRNA) expression profiles in human cancers based on experimental results. We 
also developed a software system to make the database searchable. In addition, the system 
includes an integrated miRNA sequence analysis tool for miRNAs related studies as well. The 
entire framework is named as miRCancer, and the two components are named as miRCDB and 
miRSAT, standing for miRNA-Cancer DataBase, and miRNA Sequence Analysis Tool, 
respectively. 
1.1. Motivation and Objectives 
The main motivation of this research comes from the increasing interests in miRNAs and 
the demand for an instrument which can document and offer easy access to experimental results 
for miRNAs. 
The study in miRNA is a new but rapidly increasing research area. Since the first miRNA 
was discovered in 1993, there were more than 6,000 publications about miRNAs before 2010 
and about 3,000 published in 2010. The reason that miRNA has attracted so many interests is the 
important role that miRNAs are playing in the gene expression process. Many studies show that 
miRNA is involved in regulating crucial processes. One of the most exciting involvements of 
miRNA is its association with disease. Since the heart disease and cancer are the top two killers 
for human beings, many investigations are being carried out on miRNA-based diagnostics and 
[2] 
 
therapeutics for these two diseases. Although most of the experimental results from those studies 
were clearly documented and are available to public, they are scattered in literatures. 
The large number of miRNAs and the many-to-many relationships between miRNA and 
cancers make it difficult to access miRNA-cancer research results. On one hand, the number of 
newly discovered miRNAs has been exponentially increased in recent years, from a few numbers 
of them before 2005 to over 17,000 nowadays. On the other hand, different miRNAs have 
different functionalities and may target different genes. Most miRNAs are shown to function in 
multiple cancers [1]. Some studies even pointed out that one miRNA may have different 
functions in the same type of cancer during its different development stages. 
With the above motivations, this project has the following objectives: 
 Develop an automatic text extraction module to get miRNA-cancer experimental results 
from literatures. 
 Design and construct a database which stores miRNA expression profiles in human 
cancers and detailed related information. 
 Develop an integrated miRNA sequence analysis tool including clustering and Chi-square 
analysis.  
 Design and develop a graphic user interface to facilitate database search and provide 
sequence analysis tools to analyze selected sequences. 
 
The online free database PubMed [2] was used as the literature source. Key words: 
“miRNA cancer” and “microRNA cancer” were used to search against the database. The open 
source database MySQL [3] was used for the server for database construction. The interface was 
[3] 
 
implemented in Java using NetBeans [4]. In order to communicate with the MySQL database, a 
JDBC driver and the MySQL Connector/J were used [5]. 
1.2. Structure of the Thesis 
This thesis consists of six chapters. Chapter 1 briefly introduces the context of the 
research, as well as motivations and objectives of this study. Chapter 2 summarizes the 
background and studies of miRNA and the related research about miRNA-cancers relationships. 
Similar databases and miRNA function annotations are reviewed. Chapter 3 presents the system 
design which includes graphic user interface, logic layer, storage and the data retrieval module. 
Chapter 4 describes the database design in details. The automatic miRNA-cancer relationship 
data retrieval process is introduced. Chapter 5 presents two sequence analysis tools: clustering 
and chi-square analysis. Chapter 6 documents a step-by-step illustration to setup the system. It 
also provides instructions on how to use the system for both system administrator and normal 
users. Chapter 7 summarizes the achievements of this research, and suggests possible future 
work in this area.
  
 
Chapter 2 LITERATURE REVIEW 
2.1. miRNA and Cancers 
miRNAs are a class of non-coding, about 22-nucleotide, single-stranded RNAs that 
derive from a stem–loop precursor. They regulate gene expression in various ways, for example, 
by binding to a part of one or more messenger RNAs (mRNA), resulting in inhibiting mRNA 
translation or mRNA degradation [6-7]. Many findings suggest that miRNA plays an important 
role in regulating crucial processes, such as cell proliferation [8], apoptosis [9-10], development 
[11], differentiation [12-13], and metabolism [14-15]. Nevertheless, functions of most miRNAs 
remain undiscovered.  
The first known miRNA, lin-4, was introduced in 1993. It was found in the nematode 
worm Caenorhabditis elegans and observed to down-regulate lin-14 protein translation [6]. Since 
then, several techniques have been developed to identify miRNAs. As of September 2010, over 
17,000 mature miRNA sequences have been identified with a growth of more than 6,000 in the 
past year. Increasing interest in miRNA functionality motivated several studies; as a result, many 
strategies have been invented to deduce miRNA functions. The most common approach is via 
computational prediction algorithms, such as TargetScan, PicTar, miRanda, and miRecords 
[16-19]. Commonly-used experimental methods to reveal miRNA functions include 
over-expression and silencing [1]. 
Among the inferred functions, disease association has attracted not only scientific 
attention but also business interest; there is growing funding for commercializing miRNA-based 
diagnostics and therapeutics. Cancer causes about 13% of human deaths worldwide and 26% in 
developed countries [20]. Cancer is expected to pass heart disease as the number one killer. 
[5] 
 
Cancer increases the economic burden dramatically not only on patients but also on society. 
Carcinogenesis includes “unwanted” gene mutations which induce transformation of normal 
cells, e.g., by over-activation of pro-oncogenes such as ras, src, or abl, and in-activation of tumor 
suppressors such as p53 and PTEN [21], etc. Tumorigenic gene mutations can also be induced by 
harmful environmental factors such as tobacco over-usage and UV exposure. Although research 
demonstrates that carcinogens including tobacco, radiation, and chemicals may increase the 
chance of developing cancer, the mechanism of cancer formation is yet to be identified. The fact 
that miRNA expression levels vary significantly between normal and cancer cells suggests that 
miRNA might be associated with cancer development. Indeed, miRNA fingerprints are 
recognized in all types of analyzed cancers, such as breast cancer, cervical cancer, hepatocellular 
carcinoma, lung cancer, prostate cancer, and lymphoblastic leukemia [22-27]. 
Despite the fact that abundant research investigating miRNA expressions in cancer cells 
has been carried out and some experimental results are available, they remain scattered in the 
literature. Hence this project was carried out to develop the miRCDB database to include 
information about miRNA regulation in various human cancers. Additionally, the miRSAT tool 
was developed to provide various types of computational sequence analyses which may assist 
knowledge discovery in miRNA sequences. 
2.2. miRNA Databases 
Since the term “microRNA” was formally introduced in 2001, numerous databases and 
tools have been created to store miRNA information and predict their target mRNAs. Although 
computational target prediction methods are fast for identifying potential miRNA targets, 
experimental validation of miRNA functionalities is desired. The significant increase in 
validation experiments raises the need for a database to store these results in some uniform way.  
[6] 
 
However, compared to databases providing computationally-predicted miRNA functions, 
databases storing experimental miRNA functions are rare. To the best of our knowledge, only a 
few databases recording experimental miRNA functions exist.  
2.2.1. TarBase 
TarBase, developed by the DIANA lab, is the first database which stores 
experimentally-detected miRNA targets [28]. All the information in TarBase was manually 
curated and limited to only five kinds of species: human, mouse, fruit fly, worm, and zebrafish. 
Though TarBase provided quite detailed descriptions of each target site, such as the gene and the 
location within the 3’ UTR where the miRNA binding occurs, it could not serve as a 
comprehensive data source for miRNA targeting studies due to the limited number of species and 
miRNAs. By October 2010, TarBase had collected about 170 miRNAs which is far less than the 
number of discovered miRNAs (over 17,000) or even the number of miRNAs discovered in 
human (1,038).  
2.2.2. miRBase 
The miRBase is a central online miRNA repository that is currently hosted and 
maintained at the University of Manchester [29]. miRBase provides three kinds of services: a 
searchable database of published miRNA sequences and annotation, naming service for unique 
novel miRNA genes, and miRNA target prediction. miRBase contains the most complete set of 
miRNAs than any other resources, therefore it is used as the miRNA sequence source in this 
research project. 
Currently miRBase only provides computationally predicted miRNA targets, but it is 
expected to include experimental miRNA function annotation soon [29].  
[7] 
 
2.2.3. miR2Disease 
miR2Disease records experimental miRNA expression profiles with human diseases [30]. 
Each entry in the database was manually curated which includes: miRNA id, disease name, a 
brief description of the relationship, detection method, miRNA target genes, and literature 
reference. As of November 2010, miR2Disease has recorded 349 miRNAs in 134 diseases. In 
total, it has 2,920 different entries. Although the number of miRNAs involved is far less than the 
number of human miRNAs documented, considering the limited number of experiments that has 
been done on miRNA expressions in diseases, it is likely that miR2Disease has provided the 
complete set of miRNA-disease relationships being studied so far. 
Because all the information in miR2Disease was manually documented, errors were 
likely to be introduced into the database during the data collection process. In addition, manual 
collection is a time and effort consuming process. 
2.3. miRNA Function Annotation 
The miRNA functions are annotated differently in various databases. TarBase records 
miRNA functions as miRNA and target site pairs.  From the target sites and target genes, 
miRNA functions are inferred. For miR2Disease, each miRNA is linked to one or more diseases, 
and the disease terminologies are organized according to disease ontology. Disease ontology 
identification numbers (DOID) are used in miR2Disease to identify human diseases. 
There is no uniform way to indicate miRNA functions, but there are standard ways to 
annotate miRNAs and cancers [31-32]. The international classification of diseases for oncology 
(ICD-O) [33] published by the World Health Organization serves as the tumor or cancer 
registries. The ICD-O coding was extended in this research to annotate miRNA functions in 
cancers. 
[8] 
 
2.4. Text Mining in Biomedical Literatures 
Text mining is the process to derive useful information from text using computational 
approaches or tools. The increasing number of literatures and the open access policies of many 
biomedical journals make text mining more useful for both hypothesis generation and biological 
discovery. Unlike text mining in other fields, the biomedical text mining requires not only 
computer specialists but also biologists. The biomedical text has very specialized and complex 
vocabularies. Sometimes, a good interpretation of the text literately is not enough to understand 
it and the biology background information may be needed in order to get the accurate meaning.  
Text mining has been broadly used in biomedical literatures, especially in gene and 
protein related studies due to the need to process a large number of publications [34-36]. 
Nonetheless, text mining with miRNA literatures is rarely seen, but is expected to become 
popular and useful for the following reasons: 1) miRNAs have similar nature as genes; many 
studies on genes could be applied to miRNAs as well. 2) miRNA studies have dramatically 
increased in recent years leading to significant increase in the number of papers published on 
miRNAs. 3) Though many researches on miRNA functions have been carried out, most miRNAs 
functions remains unclear. All the above reasons lead to one conclusion that tools dealing with 
large number of literatures are in demand. 
There are three text mining approaches that are commonly used in the biomedical realm: 
co-occurrence based, rule-based, and machine learning [37]. Co-occurrence is widely used as a 
simple preprocessor or filter. One example of using co-occurrence in mining miRNA 
functionalities is the miRSel [38]. Co-occurrence based systems are easy to build but have to 
deal with variants in how a concept is stated in human writings. For example, stomach cancer 
could be referred as gastric cancer, cancer in stomach, or stomach carcinoma. Rule-based system 
[9] 
 
keeps sets of rules, such as the structure of language, relevant biology facts, and collection of 
variant forms. The rule sets may be built either by hard-coding or linguistic/semantic analyzing. 
In either way, rule-based system usually takes significant amount of time to develop. Finally, the 
machine learning approach requires large number of training data which is normally expensive 
or even impossible to generate. 
  
 
Chapter 3 SYSTEM DESIGN 
The miRCancer system adopts a 3-tier architecture style which organizes subsystems into 
three layers: Graphical User Interface (GUI), Logic, and storage as shown in Figure 1. Details 
about each layer are given below. 
 
Figure 1 miRCancer System Architecture 
3.1. User Interface Layer 
The user interface layer contains two interfaces: the query interface and the result 
interface. These two interfaces allow the user to put criteria and search against the database, 
perform analysis on the sequences, and interactively view the search/analysis results.  
The GUI layer captures user’s selection and passes the information to the logic layer, 
which will further interact with the storage and compute suitable results. After the results are 
found, they are returned to GUI to display. 
3.1.1. Query Interface 
Query interface is divided into two sections: one for searching miRNA-cancer 
relationship, and the other for setting up analysis criteria and performing analyses. The first 
[11] 
 
section allows users to enter either a miRNA name or a cancer name, and search for miRNA 
profiles in cancers related to the input.  
 
Figure 2 Query Interface.  
(a). Selected by Species. (b). Selected by Associated Cancer Name. 
(c). Selected by miRNA Name. (d). Expression Pattern Options 
The second section, which is much more complicated, is formed with two parts: sequence 
selection and analysis tool selection. In sequence selection, miRNAs can be selected in multiple 
ways: by species, phylum, class, order, family, or related cancer, or by miRNA name. Selection 
could also be made by combining these approaches as shown in Figure 2. Besides selecting those 
entire sequences, a user is also allowed to specify sequence length and/or sections of sequences 
he or she is interested in. For example, one can choose sequences from the mouse that have 20 to 
23 nucleotides each, and run analysis only on nucleotides located from position 3 to 18. This 
[12] 
 
query is submitted to the system by setting “position from=3, to=18, sequence length min=20, 
max=23”, and choosing mouse in the species list. In addition, when miRNA sequences are 
chosen by associated cancer name, the option “expression pattern” is enabled, so that the user 
could state what pattern to be examined, i.e., up regulated, down regulated, or both. In the 
analysis tool selection, a user can choose to search for miRNA-cancer relationship, perform 
clustering analysis, or perform chi-square analysis. By "clustering" we refer to grouping 
miRNAs by sequence similarity. Three parameters may be set for clustering analysis: gap score 
(GAP), substitution score (SUB), and intra cluster distance threshold (INTRA). The details of the 
parameters will be explained in Chapter 5.1. 
 
Figure 3 Result Interface for miRNA-Cancer Relationship Search. 
3.1.2. Result Interface 
Result Interface is extended into two pages: showing miRNA expressions with cancers, 
and displaying analysis output in an interactive way.  
If the user enters keyword either in the miRNA name field or the cancer name field, the 
search result will be displayed in a similar way as shown in Figure 3. A summary showing the 
search keyword and number of results is displayed at the top of the window. Below that, each 
[13] 
 
relationship is presented with the miRNA name, cancer name, expression profile, and a link to 
the PubMed website for the relevant paper. Besides the linkage to PubMed, each miRNA name 
also can be clicked and will link to the miRBase web page where the details of the miRNA 
sequence are available. 
 
Figure 4 Cluster Analysis Result Interface. 
There are two result interfaces corresponding to the two analysis tools we developed. 
Cluster results are presented in a summary tree and a detailed panel. By clicking on one or 
multiple tree nodes, corresponding detailed sequence information will be presented in the detail 
panel on the right, as shown in Figure 4. The detailed information includes: the miRNA sequence 
id, sequence, and related cancer names with the types of expressions. Chi-square analysis results 
are presented in a symmetric grid where each square represents a pair of nucleotide positions in 
the miRNAs. By moving the mouse over the grid, the three labels on the top of the grid will 
[14] 
 
change their values according to the square which is pointed to by the mouse. For instance, in 
Figure 5, the mouse is currently over the cell at the 14th column and the 12th row with 
chi-square score 8.64. Moreover, the grid is shaded with different intensities so that darker 
squares have smaller chi-square values.  
 
Figure 5 Chi-square Analysis Result Interface 
3.2. Logic Layer 
The logic layer includes all computational analysis utilities and controls information flow 
between the user interface and the storage layer. Generally it acquires queries from user interface, 
and then gathers information from the storage layer. After desired manipulation, it returns results 
back to the user through interface. The core for this layer is the implementation of analysis tools, 
which is discussed in Chapter 5. All the sequence analysis algorithms are structured following a 
strategy design pattern which decouples policy-deciding class from a set of algorithms, so that 
different algorithms can be changed transparently from the user.  
3.3. Storage Layer 
The database contains the most up-to-date reported miRNA sequences by periodic (once 
a month) update from miRBase website [29], which is the central online miRNA repository. The 
miRBase database could be downloaded in the Fasta format which is used by miRCDB to update 
miRNA sequences. The miRSAT & miRCDB currently stores 17,341 matured miRNA 
[15] 
 
sequences where 2,357 are minor miRNA sequences. Each sequence has information including 
id, accession number, sequence length, indicator for minor, and the belonging species. Having a 
database that is updated periodically will ensure that it remains comprehensive and as useful as 
possible for finding patterns within and across species. 
In addition to the sequence data, all corresponding species are stored in the database as 
well. The 17,341 miRNAs are found in 142 species, and each of them is recorded into the 
database with its family, order, class, and phylum. Every miRNA sequence links with one 
species through a three to four letter species abbreviation code. For instance, any miRNA from a 
human being is linked through the code “hsa”, which is the abbreviation of homo sapiens. 
Besides miRNA sequences and species, as the name miRCDB (miRNA-Cancer DataBase) 
suggests, the database stores important information about miRNA expression profile in cancers. 
The miRNA and cancer relationships are automatically extracted from 484 published papers 
among a literature pool of size over 10,000. Together with miRSAT, the system explores 
information enclosed in the cancer-associated miRNA sequences. For example, characteristics of 
miRNAs associated with a certain cancer could be inferred by running a clustering test on the 
specific cancer.  
Furthermore, the storage layer also includes a data retrieval module which automatically 
extracts miRNA expression profiles in cancers from literatures based on text mining technique. 
This module does not have any interface for users and neither is supposed to be used by users. 
The data retrieval is designed for the system administrator to update the database periodically 
with information from the PubMed. It is recommended to update the miRNA-cancer 
relationships as often as updating the miRNA sequences. Although there were more sequences 
identified in the past year than the number of researches on miRNA profiling in cancers, it is 
[16] 
 
important to keep the miRNA expression information comprehensive for miRCDB to serve its 
functionality as it is designed. More discussions about miRCDB design and the data retrieval 
module are presented in the next chapter. 
  
 
Chapter 4 MIRCDB AND DATA RETRIEVAL 
As mentioned previously, the miRCDB is the main component of this system which 
documents miRNA expression patterns in different cancers. It collects only human cancers in the 
current version with the possibility of extending to other species in the future. The data retrieval 
module is the major contribution component which made this study novel. This chapter will 
present the structure of the database and the data retrieval process. 
4.1. miRNA-Cancer DataBase 
The entity-relationship model of the database is presented in the figure below.  
 
Figure 6 ER Diagram for miRCDB 
 
The miRCDB contains eight tables, in which five are essential and the other three are 
auxiliaries for sequence analysis. Our previous paper has discussion about the three auxiliary 
tables [39]. The corresponding relational schema is: 
 miRNA (id, accession, sequence, minor, length, speciesAbbr*) 
 Cancer (icdo, name) 
[18] 
 
 Reference (id, title, year, month, day, issn, authors, journal, volume, issue, page) 
 mirCancer (mirId*, refId*, icdo*, expression) 
 Species (Abbr, name, commName, phylum, class, order, family) 
 Cluster (id, size, maxDistance, testId*) 
 Test (id, gap, substitution, intraDistance, positionHead, positionTail, lengthMin, 
lengthMax, specs) 
 mirCluster (mirId*, clustered*) 
Primary keys are marked with underline while foreign keys are marked with “*”. 
As described in section 3.3, all miRNA entries are provided by miRBase. Each entry has 
the identification number, accession number, sequence, an integer showing whether this entry is 
a minor sequence, the length of the sequence, and a three or four letter name indicating which 
species this sequence was identified. 
All cancer data are gathered from international classification of diseases for oncology 
(ICD-O) [33]. The ICD-O has been used in cancer registries for nearly 25 years. Each instance 
includes the ICD-O code and a common name. ICD-O coding is extended in this research for its 
two substantial advantages: being widely used in medicine and biology leads to easy reference to 
the medical and biological literature; carefully structured 3rd edition ICD-O codes describe 
different cancer stages as well as morphology of the neoplasm. Some studies [40-42] found that a 
miRNA may have different expressions during different cancer development stages. More 
experiments on the miRNA expression patterns associated with stages may open a new research 
area. Descriptions of cancer behavior and morphology by ICD-O codes give the system 
extensibility for capturing miRNA expression profiles for different stages, types, and subtypes of 
cancers in the future. 
[19] 
 
Each reference refers to a published paper in the PubMed. The miRCDB stores the 
following information for each paper: the PubMed ID (PMID), article title, date the paper was 
published, ISSN number, authors’ list, the journal name where the article was published with, 
volume, issue number, and page in the journal. With the PMID, one paper could be accessed 
online by appending the id to the following web address: http://www.ncbi.nlm.nih.gov/pubmed/. 
For example: a paper with the id of 21060679 can be found at 
http://www.ncbi.nlm.nih.gov/pubmed/21060679. 
miRNA expressions in various cancers are extracted from PubMed with the search 
keywords: miRNA cancer and microRNA expression. The next section describes the extracting 
process in details. The EICD-O coding, or expression ICD-O coding, was introduced to annotate 
miRNA expressions in cancers. By adding one extra number (0 for uncertain, 1 for 
down-regulate, and 2 for up-regulate) in front of the original ICD-O code, EICD-O code is able 
to present the miRNA expression profile with not only a specific cancer but also a cancer stage. 
For example, a miRNA that up-regulates malignant serous ovarian carcinoma is coded as “2 
C56.9 M-9090/3”, in which the first digit “2” corresponds to up-regulate, while “C56.9” is the 
topography code for ovary, “M-9090” is the morphology code for struma ovarii, and the number 
“3” is the behavior meaning a malignant cancer stage. Each miRNA-to-cancer relationship is 
recorded with the EICD-O code and the reporting literature reference. Due to the fact that 
multiple experiments might be performed for the same miRNA with the same type of cancer, 
each relationship is identified by the combination of miRNA id, EICD-O code, and the PMID.  
4.2. Data Retrieval 
In order to perform the automatic data retrieval, the program should have the knowledge 
about miRNA name, cancer name, and expression vocabularies. With these three dictionaries, 
[20] 
 
the data retrieval module takes a collection of literatures, processes each literature depending on 
the keyword appearance, and then documents miRNA profiling in cancers with the associated 
reference. The Data Retrieval module is structured following the strategy design pattern that 
encapsulates algorithm implementations from client. This design allows the retrieval method to 
be modified or improved later without affecting users.  
4.2.1. Dictionary Construction and Keyword Searching 
Compared to other biology sequences, such as genes and proteins, miRNA names have 
been formalized early enough so that they are quite unified and relatively simple. Most miRNAs 
are named with the “miR” prefix, except for a few miRNAs: bantam, let-7 family, lin-4, and 
lsy-6. The genes that encode the miRNA are also named using the same prefix “mir”. To better 
differentiate with genes, matured miRNA sequences are usually named with “miR”, and minor 
sequences have a ‘*’ at the end (e.g. miR-101, cel-miR-230*). The numerical numbers are 
assigned sequentially. Because miRNAs are highly conserved between species and organisms, 
identical sequences have the same id number regardless of species (e.g. mmu-miR-23a in mouse, 
has-miR-23a in human), and letter and/or numeral suffixes are used to differentiate identical 
sequences within a species (e.g. miR-6-1 and miR-6-2 are identical). Three or four letter prefix is 
used to indicate species (e.g. cfa-miR for dogs and cel-miR for nematode). 
There are some variations of this name convention. The data retrieval process handles 
variations when searching miRNA names. The variants include: miRNA-, microRNA-, miR, 
microRNA for miR-; miRNA-let- for miR-let-; and cases without species prefix (e.g. miR-195 
for has-miR-195). 
For cancer name vocabulary, there are some deviations too. For example, gastric cancer 
is the same as stomach cancer; cancer and carcinoma are used interchangeably. 
[21] 
 
A list of 16 terms is compiled to describe relations between miRNA-cancer pairs. Seven 
of them refer to miRNA inhibit cancer: downregulation, down-regulation, downregulate, 
down-regulate, inhibit, repress, and down-regulating. Nine of them refer to oncogenic functions: 
overexpress, upregulation, upregulate, up-regulation, up-regulate, promote, high express, highly 
express, and up-regulating. 
4.2.2. Text Mining 
Because the article title and abstract usually captures the results of researches, each 
literature’s title and abstract are used as the input for data extraction. The program will find a 
miRNA-cancer relationship only when the tri-occurrences of a miRNA, a cancer name, and an 
expression term are found in a title or in the abstract. However, the tri-occurences does not 
guarantee that a relationship will be found. 
 
Figure 7 Data Retrieval Flow Chart 
 
A simplified flow chart presented in Figure 7 illustrates the flow of text processing, with 
the complete flow chart attached in Appendix A. The retrieval process takes one abstract or one 
title at a time, and starts by looking for cancer names. In the case of a title, it is treated as a single 
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sentence. If there is only one kind of cancer found, this name is used as the master cancer name, 
and the abstract is further divided into single sentences to search for expressions and miRNAs 
(route A in Figure 7). Whenever there is a miRNA-expression pair found in a single sentence, it 
joins the master cancer name to form a tri-relation: miRNA, expression, and cancer, which are 
then recorded into miRCDB as one entry. Route A is then separated into two routes A1 and A2 
to detect miRNA-expression pairs. A1 shows the case in which there is only one kind of 
expression, either up-regulate or down-regulate, within a single sentence. In this case, any 
miRNA present in the sentence is recorded with that expression and the master cancer. A2 shows 
the case in which both expressions, i.e., up-regulate and down-regulate, are found in that 
sentence. In this case, expressions and miRNAs are paired based on their locations following the 
rules below: 
 Exp1, exp2, mir1, mir2 -> both mir are paired with exp2 
 Exp1, mir1, exp2, mir2 -> mir1 paired with exp1, mir2 paired with exp2 
 Mir1, exp1, mir2, exp2 -> mir1 paired with exp1, mir2 paired with exp2 
 Mir1, mir2, exp1, exp2 -> both mir are paired with exp1 
 Mir1, exp1, exp2, mir2 -> mir1 paired with exp1, mir2 paired with exp2 
Exp1 and exp2 means different expressions. If two or more expression terms are present 
together and have the same meaning, either up-regulate or down-regulate, they are considered as 
one exp1. When multiple miRNA names are showing continuously and not interrupted by any 
expression terms, they are considered as one mir1/mir2 group. 
Route B represents the case that multiple cancer names are mentioned in one abstract. 
The abstract is divided into single sentences, and cancer names are searched again within a 
sentence. Route B1 is similar to route A, both of which pair up expressions with miRNAs in each 
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individual sentence. The only difference is that route B1 takes the cancer name from a single 
sentence while route A has a master cancer name for the abstract. Route B2 is a special case that 
within one sentence, multiple cancer names exist. This case is not attempted by the retrieval 
module; instead it simply writes the input string to a file for human user to view. The results 
show that the case represented by route B2 is rare, where there are only 4 occurrences from more 
than 10,000 papers. 
4.3. Results and Evaluation 
The data retrieval module used PubMed query result in XML format as input. In order to 
get the most complete collection of literatures related to miRNA expressions in cancers, several 
keywords were used to search against the PubMed: miRNA cancer, microRNA expression, mir 
cancer and so on. In total, 10,219 papers were processed. The PubMed provides search result in 
XML format which include all literature details including the article abstract.  
There were 827 valid miRNA expressions found from these papers. Among them, 484 
papers contributed towards the valid expressions. 180 miRNAs and 33 cancers were involved in 
these profiling. 
Compared with the miR2Disease which has 349 miRNAs in 134 diseases and totally 
2,920 different entries, the result from this research looks reasonable. Due to limited time and 
resources, no formal result evaluation was carried out. However, 12 test cases were performed to 
ensure the correctness. Appendix B provides the complete list of test cases. 
  
 
Chapter 5 MIRSAT 
The miRSAT tookit implements various tools that allow the researchers to interact with 
the database and search for miRNA features that may be of interest. Once the user selects some 
subset of the sequences in the database, an analysis tool may be used to discover features that 
characterize the selected sequences as distinct from the entire database. If such a feature is 
discovered, then we might expect that feature to have predictive power when considering 
newly-discovered miRNA sequences. 
5.1. Clustering Analysis 
Clustering is the assignment of objects into groups so that objects from the same cluster 
are more similar to each other than objects from different clusters. In sequence analysis, 
clustering is used to group homologous sequences into gene families. This is a very important 
concept in bioinformatics and evolutionary biology in general. Once an analysis is done, the 
clusters are returned to the user who may then check for any biological relevance associated with 
the clusters. Recall that these clusters are within only those strings (i.e., sequences or 
subsequences) that the researcher has chosen. This enables the researchers to investigate 
questions such as “Among the vertebrates, how closely related are those miRNAs that 
up-regulate certain cancers?” 
5.1.1. Distance Calculation 
The Needleman-Wunsch algorithm[43] was implemented in this system for calculating 
distance between sequences. The algorithm performs a global alignment on two sequences, and 
is commonly used in bioinformatics to align protein or nucleotide sequences. It is a dynamic 
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programming based algorithm, and was the first application of dynamic programming to 
biological sequence comparison. 
The scoring system could be as simple as some arbitrary numbers in this system, or be 
sophisticate using similarity matrix for aligned characters. In order to define a suitable similarity 
matrix, substitution penalty and gap penalty, expert knowledge is necessary. This system leaves 
the substitution (SUB) and gap (GAP) penalty as user input, and set the match score for all 
characters to be zero. However, it is possible to use the similarity matrix in the future, if a 
suitable similarity matrix is found.  
The global alignment technique is said to be most useful when the sequences in the query 
set are similar and of roughly equal size. Since most miRNA sequences have 20 to 23 
nucleotides, the choice of using Needleman-Wunsch is appropriate. 
5.1.2. Clustering Algorithm 
The simple single-link hierarchical clustering method is used in this project. Hierarchical 
clustering treats each data point as a singleton cluster, and then successively merges clusters until 
all points have been merged into a single remaining cluster. The distance of two closes sequences 
from each cluster is used as the distance of those two clusters. The threshold for joining two 
clusters is called INTRA in the project, and it is also left for the user to define. 
5.2. Chi-Square Analysis 
A glance at histograms of frequencies of the four RNA bases at each position in the 
miRNA sequences shows that “U” is significantly over-represented in positions 1 and 9, an 
observation that become more significant since they bound the “seed region” [44]. In this project, 
a tool was devised to promote discovery of other such phenomena beyond what a histogram 
could reveal. Here a chi-square test is used to infer correlation between the characters found in 
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two positions of the strings under consideration. For example, the user might have selected only 
those miRNAs related to mammals, and discover that among those strings, whenever there is an 
“A” in the 4th position, there is a statistically significantly high rate of occurrences of “T” in the 
17th position. When this test is selected, the user is presented with a visual representation of the 
chi-square scores for each pair of positions. By hovering the mouse over any square of the grid 
the user can see the chi-square score for the corresponding pair of positions, a level of 
significance (p-value), and whether or not the expected frequencies in the table used to compute 
the chi-square statistic invalidate the test for that position pair. The statistics packages in the 
open-source Apache commons-math was used in this project. The package is available at 
http://commons.apache.org. 
 
  
 
Chapter 6 SYSTEM SETUP AND USER MANUAL 
The system includes three java projects developed in NetBeans: CreateTables, 
parseNCBIJ, and DiscoveryMicRNA. The CreateTables project creates necessary tables in the 
database and inserts cancer, literature information and miRNA expressions into the database. The 
parseNCBIJ project implements the data retrieval module. It takes XML file as input and 
generates three text files: one for miRNA expression with cancer and paper id, one for used 
paper information, and the third one records papers that need user’s attention. The 
DiscoveryMicRNA project constructs the GUI layer as well as the logic layer. It is designed 
mainly for the users while the other two are for system administrator. 
6.1. System Dependency and Setup 
The miRCDB uses MySQL server, thus MySQL and the JDBC Driver for MySQL are 
needed. Since some of the inputs to the system are Excel files, the Jexcelapi library is also 
required. Below are the recommended steps to setup the system: 
1. Download and install MySQL. MySQL Community Server version 5.1.52 is tested to 
work with the system. 
2. Configure MySQL using its Instance Config Wizard, set password to 1, and local host to 
3306. After successful configuration, create a database named miRCDB. 
3. Download and install JDBC Driver follow the instruction from: 
http://www.developer.com/java/data/article.php/3417381 [Retrieved on Nov. 11, 2010] 
4. Download and install JExcelApi following the instructions from: 
http://www.javanb.com/netbeans/1/19762.html [Retrieved on Nov. 10, 2010] 
5. Compile and run project CreateTables, select option 1 to create tables. 
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At this point, the system has everything ready for data input. The next section illustrates 
the steps for administrator to prepare the data for miRCDB. 
6.2. Setup miRCDB 
There are four kinds of data that are essential for miRCDB: miRNA, cancer, literature, 
and relationships. System administrators are supposed to follow the steps below to prepare such 
data. 
1. Go to miRBase website download page to download the file mature.fa. 
2. Compile and run DiscoveryMicRNA, click “Update Database” -> “Load Species Table”, 
and choose the provided Species.xls file. 
3. Continue from previous step, click “Update Database” -> “Load miRNA”, and choose 
mature.fa file downloaded in step 1. 
Now miRNA and species information are inserted to miRCDB. 
4. Go to PubMed (http://www.ncbi.nlm.nih.gov/pubmed) to search for relevant keywords, 
such as miRNA expression. Send the result to a file and choose format as XML. There 
will be a file named pubmed_result.txt. Copy this file to the parseNCBIJ directory. 
5. Compile and run the parseNCBIJ project. Three files will be generated as describe at the 
beginning of this chapter. 
6. Copy the miRNA expressions and papers file generated from previous step to the given 
file microRNAcancer.xls, and put them into different sheets: mircan and reference, 
respectively.  
7. Run CreateTables again, and select option 2 to insert literature references. 
8. Run CreateTables again, and select option 4 to insert cancers.  
9. Run CreateTables again, and select option 3 to insert miRNA-cancers relationships. 
  
 
Chapter 7 FUTURE WORK AND CONCLUSION 
The miRCancer toolkit utilizes the new EICD-O coding to indicate miRNA expression in 
human cancers, and form such database on experimental results. It provides computational tools 
for miRNA sequence analysis which will assist researchers in finding miRNA sequence 
information. By using the automatic data extraction module, the system was able to retrieve all 
miRNA expressions from published literatures. As a result, the miRCDB claims itself as the first 
comprehensive database of miRNA expression profiles in human cancers based on experiments 
results.  
Current experimental researches focus mainly on human cancers; as a result, this research 
is limited to human cancers with the possibility of extending to other species in the future. 
Moreover, there are only a few numbers of studies that were carried out on miRNA 
functionalities in different cancer development stages. Therefore, this database stores miRNA 
profiles in cancer stages I to III without differentiation. However, the coding system introduced 
in this research has the possibility to capture miRNA expressions in different cancer stages. The 
miRNA expression in other animal cancers may also be included in the database in the future. 
The EICD-O coding will help to define which cancer stage the expression is at while miRNA 
sequence name itself tells the species information.  
Besides frequently updating miRNA sequences and expression information from 
miRBase and PubMed respectively, the system also provides user friendly interface to search the 
database and apply computational tools. The system is properly designed so that correctness is 
guaranteed and extendibility is offered. The strategy design pattern used in data retrieval module 
and analysis tool subsystem allows the toolkit to be improved or even substituted independently 
to users. Although sequence analysis tools are not the focus of this project, the current 
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framework allows more analysis tools to be added. There are numerous sequence analysis tools 
and data mining tools available. All miRNA sequences stored in this database could be easily 
analyzed using these tools with or without a little preprocessing.  
Last but not least, the system is currently implemented as a stand-alone Java application. 
It may be converted into a web-based version later to make it available to the public.  
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APPENDIX B: Test Cases 
Description #1. Missing expression term 
Input MicroRNAs (miRNAs) in body fluids are candidate diagnostics for a variety 
of conditions and diseases, including breast cancer. One premise for using 
extracellular miRNAs to diagnose disease is the notion that the abundance of 
the miRNAs in body fluids reflects their abundance in the abnormal cells 
causing the disease. As a result, the search for such diagnostics in body fluids 
has focused on miRNAs that are abundant in the cells of origin. Here we 
report that released miRNAs do not necessarily reflect the abundance of 
miRNA in the cell of origin. We find that release of miRNAs from cells into 
blood, milk and ductal fluids is selective and that the selection of released 
miRNAs may correlate with malignancy. In particular, the bulk of miR-451 
and miR-1246 produced by malignant mammary epithelial cells was 
released, but the majority of these miRNAs produced by non-malignant 
mammary epithelial cells was retained. Our findings suggest the existence of 
a cellular selection mechanism for miRNA release and indicate that the 
extracellular and cellular miRNA profiles differ. This selective release of 
miRNAs is an important consideration for the identification of circulating 
miRNAs as biomarkers of disease. 
Output None 
Expected Output None 
 
Description #2. Missing cancer name 
Input Aberrant overexpression of the miR-17-92 polycistron is strongly associated 
with B-cell lymphomagenesis. Recent studies have shown that miR-17-92 
down-regulates the proapoptotic protein Bim, leading to overexpression of 
Bcl2, which likely plays a key role in lymphomagenesis. However, the fact 
that Jeko-1 cells derived from mantle cell lymphoma exhibit both 
homozygous deletion of BIM and overexpression of miR-17-92 suggests 
other targets are also involved in B-cell lymphomagenesis. To identify 
essential target(s) of miR-17-92 in lymphomagenesis, we first transfected 
miR-17-92 into 2 genetically distinct B-cell lymphoma cell lines: Raji, which 
overexpress c-Myc, and SUDHL4, which overexpress Bcl2. Raji transfected 
with miR-17-19b-1 exhibited down-regulated expression of Bim and a slight 
up-regulation in Bcl2 expression. On the other hand, SUDHL4 transfectants 
showed aggressive cell growth reflecting facilitated cell cycle progression at 
the G(1) to S transition and decreased expression of CDKN1A mRNA and 
p21 protein (CDKN1A/p21) that was independent of p53 expression. 
Conversely, transfection of antisense oligonucleotides against miR-17 and 
miR-20a into Jeko-1 led to up-regulation of CDKN1A/p21, resulting in 
decreased cell growth with G(1) to S arrest. Thus, CDKN1A/p21 appears to 
be an essential target of miR-17-92 during B-cell lymphomagenesis, which 
suggests the miR-17-92 polycistron has distinct targets in different B-cell 
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lymphoma subtypes. 
Output None 
Expected Output None 
 
Description #3. Missing miRNA name 
Input Mammography is a powerful screening tool for early detection of breast 
cancer, but it has limitations in terms of both specificity and sensitivity. 
Imaging tools such as MRI that complement mammography are too costly to 
serve as first-line screens. Recently, progress has been made on blood 
markers, particularly microRNAs and proteins. There are new methods for 
protein marker discovery directly in blood, but they are limited in the number 
of patients that can be examined. An alternative is to discover markers as 
transcripts in tissues, followed by development of blood protein tests for 
those that perform best. To identify genes that are overexpressed in 
malignancy it is paramount to include normal control tissues from healthy 
individuals. Here we report the identification of potential breast cancer 
markers, including some that are overexpressed in aggressive disease. 
Output None 
Expected Output None 
 
Description #4. One miRNA, one cancer, one kind of expressions presents in an abstract. 
Input MicroRNAs (miRNAs), are ~22 nucleotides long, non-coding RNAs that 
control gene expression post-transcriptionally by binding to their target 
mRNA's 3'UTRs (untranslated regions). Due to their roles in various 
important regulatory processes and pathways, miRNAs have been implicated 
in disease mechanisms such as tumorigenesis when their expression is 
deregulated. To date, a significant number of miRNAs and their target 
messenger RNAs (mRNAs) have been identified and verified. It is generally 
accepted that miRNAs can potentially bind to many mRNAs, which brings 
the requirement of validation of these interactions. While understanding that 
such individual interactions is crucial to delineate the role of a specific 
miRNA, we took a holistic approach and analyzed global changes in the cell 
due to expression of a miRNA in a model cell line system. Our model 
consisted of MCF7 cells stably transfected with miR-125b (MCF7-125b) and 
empty vector (MCF7-EV). MiR-125b is one of the known down-regulated 
miRNAs in breast cancers. In this study we examined the global structural 
changes in MCF7 cells lacking and expressing miR-125b by Attenuated 
Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy and 
investigated the dynamic changes by more sensitive spin-labelling Electron 
Spin Resonance (ESR) spectroscopy. Our results revealed less RNA, protein, 
lipid, and glycogen content in MCF7-125b compared to MCF7-EV cells. 
Membrane fluidity and proliferation rate were shown to be lower in 
MCF7-125b cells. Based on these changes, MCF7-125b and MCF7-EV cells 
were discriminated successfully by cluster analysis. Here, we provide a novel 
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means to understand the global effects of miRNAs in cells. Potential 
applications of this approach are not only limited to research purposes. Such 
a strategy is also promising to pioneer the development of future diagnostic 
tools for deregulated miRNA expression in patient samples. 
Output miR-125b, C50.9, down-regulate 
Expected Output miR-125b, C50.9, down-regulate 
 
Description #5. One miRNA, one cancer, 2 kinds of expressions in an abstract. 
Input Lung cancer is one of the leading causes of cancer-related death worldwide. 
Curcumin has been reported to have an antitumor effect by inducing 
apoptosis and suppressing growth of tumor cells. However, the mechanism 
by which curcumin exerts its anti-cancer effect needs further research. The 
purpose of the present study was to identify a miRNA-mediated mechanism 
which plays a role in the anti-cancer effects of curcumin. Alterations in 
miRNA expression were seen in curcumin-treated A549 cells, including 
significant downregulation of miRNA-186* expression by microarray 
analysis and real-time PCR. The miRNA-186* functions by overexpression 
or inhibition were investigated using biological assays in A549 cells. 
Additionally, caspase-10 was identified as a target of miRNA-186* using 
dual luciferase reporter assays and western blot analysis. These results 
demonstrate that curcumin induces A549 cell apoptosis through a miRNA 
pathway. Also, miRNA-186* could serve as a potential gene therapy target 
in curcumin treatment. furthermore, caspase-10 was shown to be a target of 
miR-186* regulation.<PMID>20878113 
Output miR-186*, C34.9, down-regulate 
Expected Output miR-186*, C34.9, down-regulate 
 
Description #6. One miRNA, multiple cancers, two kinds of expressions in an abstract.  
Input OBJECTIVE: MicroRNA (miRNA) plays an essential role in the progression 
of a variety of cancers, but its role in cervical cancer progression is not well 
defined. We aimed to test whether special miRNAs and their target mRNAs 
contribute to cervical cancer progression.METHODS: The expression 
profiles of 1145 microRNAs in cervical squamous cell carcinomas (CSCC) 
and adjacent non-tumor tissues were investigated using an Illumina 
microRNA microarray platform. Differentially expressed miRNAs were 
validated by RT-PCR. Downstream target validation was performed for 
miR-886-5p.RESULTS: We found that the expression levels of seven 
miRNAs differed significantly between CSCC tissues and adjacent 
non-tumor tissues. Forced expression of one miRNA, miR-886-5p, 
over-expressed in CSCC tissues lowered expression of the pro-apoptotic 
protein Bax, reduced apoptosis and promoted cell proliferation in H8, an 
HPV16-immortalized human cervical squamous epithelial cell line. 
Knockdown of miR-886-5p increased Bax protein and apoptotic cell death in 
cells of the cervical squamous carcinoma cell line, SiHa.CONCLUSION: 
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MicroRNA miR-886-5p inhibits apoptosis of cervical cancer cells by 
down-regulating the production of Bax. 
Output miR-886-5p, C53.9, up-regulate 
Expected Output miR-886-5p, C53.9, up-regulate 
 
Description #7. Multiple miRNA, one cancer, two kinds of expressions in an abstract. 
Input This study aimed to investigate the microRNA (miRNA) profile in prostate 
carcinoma tissue by microarray analysis and RT-qPCR, to clarify 
associations of miRNA expression with clinicopathologic data and to 
evaluate the potential of miRNAs as diagnostic and prognostic markers. 
Matched tumor and adjacent normal tissues were obtained from 76 radical 
prostatectomy specimens. Twenty-four tissue pairs were analyzed using 
human miRNA microarrays for 470 human miRNAs. Differentially 
expressed miRNAs were validated by TaqMan RT-qPCR using all 76 tissue 
pairs. The diagnostic potential of miRNAs was calculated by receiver 
operating characteristics analyses. The prognostic value was assessed in 
terms of biochemical recurrence using Kaplan-Meier and Cox regression 
analyses. Fifteen differentially expressed miRNAs were identified with 
concordant fold-changes by microarray and RT-qPCR analyses. Ten 
microRNAs (hsa-miR-16, hsa-miR-31, hsa-miR-125b, hsa-miR-145, 
hsa-miR-149, hsa-miR-181b, hsa-miR-184, hsa-miR-205, hsa-miR-221, 
hsa-miR-222) were downregulated and 5 miRNAs (hsa-miR-96, 
hsa-miR-182, hsa-miR-182, hsa-miR-183, hsa-375) were upregulated. 
Expression of 5 miRNAs correlated with Gleason score or pathological 
tumor stage. Already 2 microRNAs classified up to 84% of malignant and 
nonmalignant samples correctly. Expression of hsa-miR-96 was associated 
with cancer recurrence after radical prostatectomy and that prognostic 
information was confirmed by an independent tumor sample set from 79 
patients. That was shown with hsa-miR-96 and the Gleason score as final 
variables in the Cox models build in the 2 patient sets investigated. Thus, 
differential miRNAs in prostate cancer are useful diagnostic and prognostic 
indicators. This study provides a solid basis for further functional analyses of 
miRNAs in prostate cancer. 
Output hsa-miR-16, C61.9, down-regulate 
hsa-miR-31, C61.9, down-regulate 
hsa-miR-125b, C61.9, down-regulate 
hsa-miR-145, C61.9, down-regulate 
hsa-miR-149, C61.9, down-regulate 
hsa-miR-181b, C61.9, down-regulate 
hsa-miR-184, C61.9, down-regulate 
hsa-miR-205, C61.9, down-regulate 
hsa-miR-221, C61.9, down-regulate 
hsa-miR-222, C61.9, down-regulate 
hsa-miR-96, C61.9, up-regulate 
hsa-miR-182, C61.9, up-regulate 
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hsa-miR-182, C61.9, up-regulate 
hsa-miR-183, C61.9, up-regulate 
hsa-375, C61.9, up-regulate 
Expected Output hsa-miR-16, C61.9, down-regulate 
hsa-miR-31, C61.9, down-regulate 
hsa-miR-125b, C61.9, down-regulate 
hsa-miR-145, C61.9, down-regulate 
hsa-miR-149, C61.9, down-regulate 
hsa-miR-181b, C61.9, down-regulate 
hsa-miR-184, C61.9, down-regulate 
hsa-miR-205, C61.9, down-regulate 
hsa-miR-221, C61.9, down-regulate 
hsa-miR-222, C61.9, down-regulate 
hsa-miR-96, C61.9, up-regulate 
hsa-miR-182, C61.9, up-regulate 
hsa-miR-182, C61.9, up-regulate 
hsa-miR-183, C61.9, up-regulate 
hsa-375, C61.9, up-regulate 
 
Description #8. Multiple miRNA, multiple cancers, one expression in an abstract. 
Input RESULTS: A set of 4 human micro-RNAs (miR-28, miR-185, miR-27, and 
let-7f-2) were found significantly up-regulated in renal cell carcinoma (P < 
0.05) compared to normal kidney. Human micro-RNAs miR-223, miR-26b, 
miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, 
and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) 
compared to normal bladder mucosa. Of the kidney cancers studied, there 
was no differential micro-RNA expression across various stages, whereas 
with increasing tumor-nodes-metastasis staging in bladder cancer, miR-26b 
showed a moderate decreasing trend (P = 0.082).PMID: 17826655 
Output miR-103-1, C67.9, up-regulate 
miR-28, C64.9, M8312/3, up-regulate 
miR-27, C64.9, M8312/3, up-regulate 
miR-23a, C67.9, up-regulate  
miR-17-5p, C67.9, up-regulate 
miR-23b, C67.9, up-regulate 
miR-185, C64.9, M8312/3, up-regulate 
miR-26b, C67.9, up-regulate 
miR-205, C67.9, up-regulate  
miR-185, C67.9, up-regulate 
miR-221, C67.9, up-regulate 
miR-203, C67.9, up-regulate 
let-7f-2, C64.9, M8312/3, up-regulate 
miR-223, C67.9, up-regulate 
Expected Output miR-28, C64.9, M8312/3, up-regulate 
miR-185, C64.9, M8312/3, up-regulate 
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miR-27, C64.9, M8312/3, up-regulate 
let-7f-2, C64.9, M8312/3, up-regulate 
miR-223, C67.9, up-regulate 
miR-26b, C67.9, up-regulate 
miR-221, C67.9, up-regulate 
miR-103-1, C67.9, up-regulate 
miR-185, C67.9, up-regulate 
miR-23b, C67.9, up-regulate 
miR-203, C67.9, up-regulate 
miR-17-5p, C67.9, up-regulate 
miR-23a, C67.9, up-regulate 
miR-205, C67.9, up-regulate 
 
Description #9. Tri-relation exists, but miRNA-expression pair not exists in any single 
sentences. 
Input In this study, we quantified 249 mature micro-RNA (miRNA) transcripts in 
estrogen receptor-positive (ER(+)) primary breast tumors of patients with 
lymph node-negative (LNN) disease to identify miRNAs associated with 
metastatic capability. In addition, the prognostic value of the candidate 
miRNAs was determined in ER(-)/LNN breast cancer. Unsupervised analysis 
in a prescreening set of 38 patients identified three subgroups predominantly 
driven by three miRNA signatures: an ER-driven luminal B-associated 
miRNA signature, a stromal miRNA signature, and an overexpressed 
miRNA cluster located on chromosome 19q23, but these intrinsic miRNA 
signatures were not associated with tumor aggressiveness. Supervised 
analysis in the initial subset and subsequent analysis in additional tumors 
significantly linked four miRNAs (miR-7, miR-128a, miR-210, and 
miR-516-3p) to ER(+)/LNN breast cancer aggressiveness (n = 147) and one 
miRNA (miR-210) to metastatic capability in ER(-)/LNN breast cancer (n = 
114) and in the clinically important triple-negative subgroup (n = 69) (all P < 
0.05). Bioinformatic analysis coupled miR-210 to hypoxia/VEGF signaling, 
miR-7 and miR-516-3p to cell cycle progression and chromosomal 
instability, and miR-128a to cytokine signaling. In conclusion, our work 
connects four miRNAs to breast cancer progression and to several distinct 
biological processes involved therein. PMID: 18755890 
Output None 
Expected Output None 
 
Description #10. Cancer name conventions. (non-small cell lung cancer vs. lung 
cancer) 
Input Following the identification of a set of hypoxia-regulated microRNAs 
(miRNAs), recent studies have highlighted the importance of miR-210 and of 
its transcriptional regulation by the transcription factor hypoxia-inducible 
factor-1 (HIF-1). We report here that miR-210 is overexpressed at late stages 
[41] 
 
of non-small cell lung cancer. Expression of miR-210 in lung 
adenocarcinoma A549 cells caused an alteration of cell viability associated 
with induction of caspase-3/7 activity. miR-210 induced a loss of 
mitochondrial membrane potential and the apparition of an aberrant 
mitochondrial phenotype. The expression profiling of cells overexpressing 
miR-210 revealed a specific signature characterized by enrichment for 
transcripts related to 'cell death' and 'mitochondrial dysfunction', including 
several subunits of the electron transport chain (ETC) complexes I and II. 
The transcript coding for one of these ETC components, SDHD, subunit D of 
succinate dehydrogenase complex (SDH), was validated as a bona fide 
miR-210 target. Moreover, SDHD knockdown mimicked miR-210-mediated 
mitochondrial alterations. Finally, miR-210-dependent targeting of SDHD 
was able to activate HIF-1, in line with previous studies linking 
loss-of-function SDH mutations to HIF-1 activation. miR-210 can thus 
regulate mitochondrial function by targeting key ETC component genes with 
important consequences on cell metabolism, survival and modulation of 
HIF-1 activity. These observations help explain contradictory data regarding 
miR-210 expression and its putative function in solid tumors.Cell Death and 
Differentiation advance online publication, 1 October 2010; 
doi:10.1038/cdd.2010.119.pmid:20885442 
Output miR-210, C34.9, M8046/3, up-regulate 
Expected Output miR-210, C34.9, M8046/3, up-regulate 
 
Description #11. MiRNA name variations. MiRNA vs miR. 
Input PURPOSE: To investigate the different miRNA expression profiles of 
postoperative radiotherapy sensitive and resistant patients of non-small cell 
lung cancer, explore their potential role and find some radio-sensitivity 
markers. MATERIALS AND METHODS: Thirty non-small cell lung cancer 
patients who have been treated by postoperative radiotherapy were selected 
and were divided into radiotherapy sensitive group and resistant group 
according to overall survival and local or distant recurrence rate. Expression 
profile of miRNA in these two groups was detected by a microarray assay 
and the results were validated by quantitative RT-PCR and Northern blot. At 
the molecular level, the effect of one differently expressed miRNA 
(miR-126) on the growth and apoptosis of SK-MES-1 cells induced by 
irradiation was examined. RESULTS: Comparing with resistant patients, five 
miRNAs (miRNA-126, miRNA-let-7a, miRNA-495, miRNA-451 and 
miRNA-128b) were significantly upregulated and seven miRNAs 
(miRNA-130a, miRNA-106b, miRNA-19b, miRNA-22, miRNA-15b, 
miRNA-17-5p and miRNA-21) were greatly downregulated in radiotherapy 
sensitive group. Overexpression of miRNA-126 inhibited the growth of 
SK-MES-1 cells and promoted its apoptosis induced by irradiation. The 
expression level of p-Akt decreased in miRNA-126 overexpression group. 
After treating with phosphoinositidyl-3 kinase (PI3K) constitutively activator 
(IGF-1) and inhibitor (LY294002), miRNA-126 overexpression had no 
[42] 
 
significant effects on the apoptosis of SK-MES-1 cells. CONCLUSION: We 
found 12 differently expressed miRNAs in the radiotherapy sensitive and 
resistant non-small cell lung cancer samples. Moreover, our results showed 
miRNA-126 promoted non-small cell lung cancer cells apoptosis induced by 
irradiation through the PI3K-Akt pathway.pmid:20728239 
Output miR-19b, C34.9, M8046/3, down-regulate 
miR-128b, C34.9, M8046/3, up-regulate 
miR-let-7a, C34.9, M8046/3, up-regulate 
miR-495, C34.9, M8046/3, up-regulate 
miR-126, C34.9, M8046/3, up-regulate 
miR-451, C34.9, M8046/3, up-regulate 
miR-106b, C34.9, M8046/3, down-regulate 
miR-17-5p, C34.9, M8046/3, down-regulate 
miR-130a, C34.9, M8046/3, down-regulate 
miR-21, C34.9, M8046/3, down-regulate 
miR-22, C34.9, M8046/3, down-regulate 
miR-15b, C34.9, M8046/3, down-regulate 
miR-126, C34.9, M8046/3, down-regulate 
Expected Output miR-126, C34.9, M8046/3, up-regulate 
miR-let-7a, C34.9, M8046/3, up-regulate 
miR-495, C34.9, M8046/3, up-regulate 
miR-451, C34.9, M8046/3, up-regulate 
miR-128b, C34.9, M8046/3, up-regulate 
miR-130a, C34.9, M8046/3, down-regulate 
miR-106b, C34.9, M8046/3, down-regulate 
miR-19b, C34.9, M8046/3, down-regulate 
miR-22, C34.9, M8046/3, down-regulate 
miR-15b, C34.9, M8046/3, down-regulate 
miR-17-5p, C34.9, M8046/3, down-regulate 
miR-21, C34.9, M8046/3, down-regulate 
 
Description #12. Multiple cancers in a single sentence. 
Input MicroRNAs (miRNAs) are short noncoding RNA molecules, which 
posttranscriptionally regulate genes expression and play crucial roles in 
diverse biological processes, such as development, differentiation, apoptosis 
and proliferation. Here, we investigated the possible role of miRNAs in the 
development of multidrug resistance (MDR) in human gastric and lung 
cancer cell lines. We found that miR-181b was downregulated in both 
multidrug-resistant human gastric cancer cell line SGC7901/vincristine 
(VCR) and multidrug-resistant human lung cancer cell line A549/cisplatin 
(CDDP), and the downregulation of miR-181b in SGC7901/VCR and 
A549/CDDP cells was concurrent with the upregulation of BCL2 protein, 
compared with the parental SGC7901 and A549 cell lines, respectively. In 
vitro drug sensitivity assay demonstrated that overexpression of miR-181b 
sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, 
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respectively. The luciferase activity of a BCL2 3'-untranslated region-based 
reporter construct in SGC7901/VCR and A549/CDDP cells suggests that a 
new target site in the 3'UTR of BCL2 of the mature miR-181s (miR-181a, 
miR-181b, miR-181c and miR-181d) was found. Enforced miR-181b 
expression reduced BCL2 protein level and sensitized SGC7901/VCR and 
A549/CDDP cells to VCR-induced and CDDP-induced apoptosis, 
respectively. Taken together, our findings suggest that miR-181b could play 
a role in the development of MDR in both gastric and lung cancer cell lines, 
at least in part, by modulation of apoptosis via targeting BCL2. 
Output Write to file 
Expected Output Write to file 
 
 
